Predicting amyloid-beta pathology in the general population.

ABSTRACT:

Introduction

Reliable models to predict amyloid beta (Aβ) positivity in the general aging population are lacking but could become cost-efficient tools to identify individuals at risk of developing Alzheimer's disease.

Methods

We developed Aβ prediction models in the clinical Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) Study (n = 4,119) including a broad range of easily ascertainable predictors (demographics, cognition and daily functioning, health and lifestyle factors). Importantly, we determined the generalizability of our models in the population-based Rotterdam Study (n = 500).

Results

The best performing model in the A4 Study (area under the curve [AUC] = 0.73 [0.69-0.76]), including age, apolipoprotein E (APOE) ε4 genotype, family history of dementia

SUBMITTER: Nguyen Ho PT 

PROVIDER: S-EPMC7616996 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature